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KEY POINTS: 
• PF-04691502 induces potent apoptosis in CLL cells and supresses pro-survival anti-IgM 
signaling and CXCL12-induced migration.  
• PF-04691502 displays powerful anti-tumor effects in vivo in the Eµ-TCL1 mouse model   
 
ABSTRACT  
Current treatment strategies for CLL involve a combination of conventional chemotherapeutics, 
monoclonal antibodies and targeted signaling inhibitors. However, CLL remains largely incurable with 
drug resistance and treatment relapse a common occurrence; leading to the search for novel 
treatments. mTOR specific inhibitors have been previously assessed but their efficacy is limited due to 
a positive feedback loop via mTORC2, resulting in activation of pro-survival signaling. Here we show 
that the dual PI3K/mTOR inhibitor PF-04691502 does not induce an mTORC2 positive feedback loop 
similar to other PI3K inhibitors but does induce substantial anti-tumor effects. PF-04691502 
significantly reduced survival coincident with the induction of Noxa and Puma, independently of IGHV 
mutational status, CD38 and ZAP-70 expression. PF-04691502 inhibited both anti-IgM induced 
signaling and overcame stroma-induced survival signals as well as migratory stimuli from CXCL12. 
Equivalent in vitro activity was seen in the Eµ-TCL-1 murine model of CLL. In vivo, PF-04691502 
treatment of tumor-bearing animals resulted in a transient lymphocytosis, followed by a clear 
reduction in tumor in the blood, bone marrow, spleen and lymph nodes. These data indicate that PF-
04691502 or other dual PI3K/mTOR inhibitors in development may prove efficacious for the treatment 
of CLL, increasing our armamentarium to successfully manage this disease.  
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INTRODUCTION 
Chronic Lymphocytic Leukemia (CLL) is characterized by the accumulation of CD5+CD19+ cells in the 
peripheral blood, lymph nodes and bone marrow. Several prognostic markers are associated with 
progressive disease; these include unmutated immunoglobulin heavy chain variable regions (IGHV) 
and high expression of CD38 and ZAP-70.1 Current treatment strategies involve the combination of 
fludarabine, cyclophosphamide and rituximab,2 however CLL largely remains incurable with drug 
resistance and treatment relapse a common occurrence.3  
 
Recently, inhibitors targeting key signaling molecules such as BTK (ibrutinib) and PI3K (idelalisib) have 
been approved,4,5 due to exceptional clinical responses.6-11 In this regard, the PI3K/mTOR pathway is 
particularly attractive because it is activated upon ligation of various chemokine and cytokine 
receptors expressed by CLL cells as well as following B cell receptor (BCR) engagement.12 Class 1 PI3Ks 
are divided into Class 1A (PI3Kα, PI3Kβ and PI3Kδ) and Class 1B (PI3Kγ) isoforms. The expression of 
PI3Kδ and PI3Kγ is largely restricted to leukocytes, whilst the expression of PI3Kα and PI3Kβ is 
ubiquitous. PI3Kδ and PI3Kγ have crucial roles in a plethora of leukocyte functions including 
proliferation, antibody secretion, survival, migration13 and ROS generation.14 Functional redundancy 
between PI3K isoforms is evident and supported by the fact that multiple isoforms require inhibition 
to fully reverse the neutrophil survival induced by GM-CSF.15 PI3K exists in a complex signaling network 
with multiple partners including those regulating mTOR. mTOR-complex-1 (mTORC1) is a 
serine/threonine kinase activated downstream of PI3K which controls protein translation, growth and 
proliferation in part via modulation of S6 ribosomal subunit activity.16 In contrast, mTOR complex 2 
(mTORC2) phosphorylates AKTS473 and is required for maximal activation of AKT16 (Supplementary 
Figure 1A and B). 
 
PI3K signaling is known to be overactive in CLL,17 with patients with unmutated IGHV having increased 
PI3K gene expression compared to patients with mutated IGHV.18 The PI3Kδ selective inhibitor 
Idelalisib has been approved by the FDA to treat CLL patients with relapsed disease in combination 
with rituximab.4 Idelalisib inhibits chemokine- and BCR-induced signaling and sensitizes CLL cells to 
standard genotoxic agents.19-21 In patients, Idelalisib has a dual mechanism of action: 1) directly 
reducing CLL cell viability; and 2) disrupting stromal cell interactions and releasing CLL cells from their 
protective microenvironments into the blood, where they are more susceptible to chemotherapy-
induced apoptosis. However single isoform inhibitors against PI3Kα/β/δ and pan-class1 PI3K inhibitors 
in CLL cells have all been reported to induce apoptosis.22,23 Pharmacological inhibition of mTOR 
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induces cell cycle arrest and apoptosis in CLL cells,24-26 however prolonged inhibition of mTOR is known 
to disrupt negative feedback loops and cause increased AKTS473 activation in other malignancies.27,28 
 
Given the important role of both PI3K and mTOR in CLL cell survival, the dual pharmacological 
inhibition of both Class 1 PI3K and mTOR signaling may offer new therapeutic potential, with the 
possibility of deeper remissions or as an alternative following resistance to idelalisib. PF-04691502 is 
a potent selective dual Class 1 pan-PI3K/mTOR inhibitor29 shown to inhibit tumor growth and to 
promote apoptosis in solid tumors.29-33 PF-04691502 inhibits (IC50) PI3Kδ 1.6nM(Ki), PI3Kα 1.8nM(Ki), 
PI3Kγ 1.9nM(Ki), PI3Kβ 2.1nM(Ki) and in cells has shown IC50 values of 3.8nM and 7.5nM for P-AKTS473 
and P-AKTT308, respectively.29 During phase I clinical trials, PF-04691502 was shown to have a similar 
safety profile to other PI3K inhibitors.34  
 
In this study we showed in primary CLL cells that PF-04691502 induced caspase-dependent apoptosis. 
In contrast, little effect on the viability of normal B and T lymphocytes was evident. BCR and CXCR4 
stimulated signaling was inhibited by PF-04691502 and chemokine mediated motility was potently 
reduced. Similarly impressive anti-tumor effects were seen with the Eµ-TCL1 murine CLL-like cells in 
vitro and in vivo. Together these data indicate that concomitant targeting of mTOR and PI3K is a 
powerful approach for treating CLL. 
 
MATERIALS AND METHODS 
Patients and cells 
Diagnosis of CLL was according to the IWCLL-NCI 2008 criteria.35 Forty-nine CLL isolates were studied 
following informed written consent in accordance with ethics committee approvals under the 
declaration of Helsinki (reference 228/02/t) (Supplementary Table 1). Procedures for the isolation of 
malignant cells and the determination of their purity have been described previously.36 All isolates 
contained >90% CD19+CD5+ cells. Normal B and T lymphocytes from peripheral blood were taken from 
healthy age-matched controls as previously described.37  
 
Reagents 
Tissue culture materials were from life technologies (Paisley, UK). ZVAD.fmk was from Enzo life 
sciences (Exeter, UK). PF-04691502 was provided by Pfizer Inc. and purchased from Selleckchem for 
in vivo studies (Houston USA). Idelalisib, BYL719, Everolimus, GSK2636771, and AS-605240 and were 
from Selleckchem (Houston, USA). Annexin-V was from the Southampton CR-UK core proteomics 
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facility. Anti-IgM was from Cambridge Bioscience (Cambridge, UK) and CXCL12 from Miltenyi (Bisley, 
UK). HFFF2 cells were a kind gift from Prof. Thomas (University of Southampton). 
 
Cell culture and protein extraction 
CLL cell culture and protein extraction for immunoblotting were as previously described.38,39 Soluble 
anti-IgM was used at 20µg/ml, bead bound immobilised anti-IgM was added at 2:1 ratio, bead:CLL cell. 
Densitometry of immunoblots are depicted in Supplementary Figures 6 and 7.  
 
Gel electrophoresis and Immunoblotting 
Proteins were separated on 12% polyacrylamide gels (LifeTechnologies, Paisley Scotland), transferred 
to nitrocellulose membranes (GE Healthcare, Buckinghamshire, UK) and probed with antibodies listed 
in Supplementary Table 2. Bands were detected by incubation with HRP-linked secondary antibodies 
(Dako), enhanced chemiluminescence reagents (Thermo Scientific, Rockford, IL) and visualised using 
the ChemiDoc-It imaging system (UVP). Band intensities were quantified using ImageJ. 
 
Viability assays 
CLL cells were treated with PF-04691502 for 24h and viability assessed by Annexin V-FITC and 
propidium iodide (PI) negativity as previously described.39 Fifty percent inhibitory concentration 
values (IC50) were measured using CalcuSyn software (Biosoft, Cambridge). Peripheral blood 
mononuclear cells from normal donors were plated at 1×106cells/ml, treated with PF-04691502 for 
24h and normal T and B cells labelled with APC conjugated anti-CD3 or anti-CD19 respectively, in 
combination with Annexin V-FITC/PI.37  
 
Eµ-TCL1 experiments 
In vitro analysis using Eµ-TCL1 cells were performed at 2.5 x106 cells/ml. For in vivo experiments, 1x107 
Eµ-TCL1 leukemia cells were given by intra-peritoneal injection to congenic, age-matched female 
C57BL/6 mice, n= 7 per group. Leukemic burden was assessed by tail bleeding, and monitoring total 
lymphocyte counts and the percentage of CD5+B220lo cells by flow cytometry. PF-04691502 was 
administered in 0.5% methylcellulose by oral gavage at either 5 or 10mg/kg/day. Animals were 
sacrificed and organs harvested for further analysis. Total organ tumor burden was calculated by 
CD5+B220lo flow cytometry using quanti-bright counting beads (Life Technologies, UK). 
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RESULTS 
mTOR inhibition of CLL cells augments AKTS473 signaling 
Previous studies in other tumor systems have shown that inhibition of mTOR with 
everolimus/rapamycin results in augmentation of the mTORC2 target, AKTS473.27,28 Here we show that 
this also occurs in CLL cells both in resting conditions and more effectively following BCR engagement 
with soluble anti-IgM antibodies (Figure 1A and 1B) with the expected effects on the mTOR target 
phosphorylated (p)S6 kinase (pS6K) (Figure 1C). In contrast, the dual PI3K/mTOR inhibitor PF-
04691502 does not induce hyperphosphorylation of AKTS473 and inhibits the pathway as shown with 
other PI3K inhibitors (Supplementary Figure 1C). Phosphorylated-S6K was completely abrogated with 
PF-04691502, whilst phosphorylated S6 ribosomal protein (pS6S235/236) is regulated by both the MAPK 
and PI3K/mTOR signalling pathways and was therefore only partially affected by both everolimus and 
PF-04691502 (Figure 1D). AKT is also phosphorylated at AKTT308 in a PI3K-dependent manner by PDK 
and was not significantly augmented by everolimus treatment before or after anti-IgM treatment. 
However, PF-04691502 completely abrogated AKTT308 phosphorylation (Figure 1E). Together these 
data indicate that the same negative feedback loop involving mTORC2 is in operation in CLL cells but 
is circumvented by PF-04691502. 
 
PF-04691502 reduces cell viability in CLL cells independently of prognostic markers 
CLL samples were treated with PF-04691502 and viability assessed using annexin-V/PI staining 
(Supplementary Figure 2A). PF-04691502 reduced viability of CLL cells after 24, 48 and 72h hours 
(Figure 2A & 2B) with a mean IC50 of 0.96µM (median 0.65µM), 0.32µM and 0.25µM, respectively. The 
same CLL samples treated with idelalisib did not reach its IC50 value up to 40μM (Figure 2A) in 
agreement with the literature.19,20 Normal B and T cells from age-matched controls were largely 
unaffected by PF-04691502 over a similar dose range. No significant differences in mean IC50 values 
for PF-04691502 were observed between unmutated (U-CLL) and mutated (M-CLL) IGHV genes (Figure 
2B), high and low ZAP-70 (>30%)  (Figure 2C) or CD38 expression (>30%)  (Figure 2D). However a trend 
for lower IC50 values was observed in U-CLL compared to M-CLL. Furthermore, three CLL samples with 
17p del (2/3 samples >70% 17p del by FISH) were as susceptible to PF-04691502-induced death as 
wildtype samples (Supplementary Figure 2B), indicating that PF-04691502 may also have activity 
independent of 17p del status.  
 
Combination of isoform specific PI3K inhibitors and an mTOR inhibitor mimic PF-04691502 
PF-04691502 reduced viability of CLL cells to a greater extent compared to idelalisib. Therefore, we 
sought to determine whether we could replicate its efficacy using a combination of isoform-specific 
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PI3K inhibitors including BYL719 (PI3Kα inhibitor), GSK2636771 (PI3Kβ inhibitor), idelalisib (PI3Kδ 
inhibitor), AS-605240 (PI3Kγ inhibitor) in combination with the mTOR inhibitor everolimus (mTORC1 
inhibitor). Each inhibitor alone (1μM) reduced viability by no more than ~10% (Supplementary Figure 
2C). This was in contrast to PF-04691502, which at the same concentration reduced CLL cell viability 
by >50%. The combination of all five selective inhibitors at 1µM significantly reduced CLL cell viability 
more than any of the inhibitors alone, albeit significantly less than PF-04691502 (p=0.004, n=11). 
Finally we showed that a combination of idelalisib with everolimus was significantly more efficacious 
than either agent alone (p=0.02 and p=0.01) (Supplementary Figure 2D) but significantly less than PF-
04691502 (p=0.03). Together these data suggests that PF-04691502 likely achieves its robust killing 
effects through simultaneous inhibition of mTORC1, mTORC2 and PI3Kδ.  
 
PF-04691502 induces apoptosis in a caspase-dependent mechanism 
To determine the mechanism of death induced by PF-04691502, we first investigated expression of 
key pro-apoptotic BH3-only proteins Noxa, Puma, Bad, Bim and Bax, and anti-apoptotic Bcl-2 family 
proteins Mcl-1 and Bcl-2 which regulate apoptosis within CLL cells. Incubation with PF-04691502 (0.31-
1.25µM) induced Noxa and Puma expression (protein and mRNA) in a dose-dependent manner (Figure 
3A and data not shown). No significant changes were observed for Bim, Bad, Bcl-2 or Mcl-1 (data not 
shown). Basal pAKTS473 and pS6KT389 were inhibited by PF-04691502 as expected. In response to pro-
apoptotic stimuli, Bax undergoes a conformational change and subsequently becomes inserted into 
the outer mitochondrial membrane where it facilitates cytochrome c release and subsequent 
apoptosis. Using the conformational change specific 6A7 antibody37 we showed that CLL cells 
incubated with PF-04691502 produced a marked increase in the active, mitochondrially-resident 
conformation of Bax (Figure 3B). Furthermore treatment of CLL cells with PF-04691502 (0.31-5µM) for 
18 hours induced caspase-3 cleavage and subsequent appearance of the p85 cleaved sub-fragment of 
PARP (Figure 3C). To confirm PF-04691502 induced apoptosis of CLL cells in a caspase-dependent 
manner, we treated cells with the pan-caspase inhibitor ZVAD.fmk. ZVAD.fmk significantly prevented 
the PF-04691502 induced decrease in cell viability even at the highest concentrations of PF-04691502 
(20µM) (p<0.001, n=7) (Figure 3D). 
 
PF-04691502 reduced viability of CLL cells in co-culture with stromal cells 
CLL cells are known to receive key survival signals from stromal cells in the bone marrow and lymph 
nodes, reducing CLL apoptosis and promoting drug resistance.12 Therefore, we investigated the effect 
of PF-04691502 upon CLL cells co-cultured with human stromal fibroblast cells (HFFF2) which we have 
observed can provide anti-apoptotic signaling to CLL cells (manuscript in preparation). PF-04691502 
7 
 
significantly inhibited signaling induced by HFFF2 (Supplementary Figure 3A) and reduced CLL cell 
viability (p=0.016), thus showing its ability to overcome stromal support (Figure 3E). To preclude that 
its activity was due to a direct cytotoxic effect on the fibroblasts (Supplementary Figure 3B) we also 
performed “wash-out” experiments where PF-04691502 was added to the CLL cells for 1h and washed 
off prior to addition to the HFFF2 cells. Cell viability was still significantly reduced by PF-04691502 
(p=0.016) and downstream signaling inhibited in this setting (Figure 3F, Supplementary Figure 3C).  
 
Dual PI3K/mTOR inhibition decreases pro-survival BCR signaling  
Ligation of the CLL BCR by antigen/autoantigen is thought to primarily occur in the lymph nodes, acting 
to enhance CLL survival and resistance to chemotherapy.40 Antigen in lymph nodes may be present in 
both soluble and membrane bound forms. Therefore, we utilised both soluble and bead-immobilised 
anti-IgM41 to investigate the effect of PF-04691502 (2.5-2500nM) on BCR signaling. Analysis of 
downstream signaling showed that both the soluble (Figure 4A) and bead-immobilised (Figure 4B) 
anti-IgM induced strong activation of pAKTS473/T308, pERKT202/Y204, pS6KT389 and pS6S235/236 ribosomal 
subunit. PF-04691502 significantly inhibited pAKTS473/T308 and pS6KT389 in CLL samples following both 
soluble and immobilised anti-IgM treatment and at concentrations below maximum achievable 
plasma drug concentrations (100-200nM).34 pERKT202/Y204 and pS6S235/236 were significantly inhibited by 
PF-04691502 following soluble (Figure 4A) but not immobilised (Figure 4B) anti-IgM treatment. These 
data indicate that PF-04691502 inhibits PDK1-mediated pAKTT308, mTORC1-induced pS6KT389 and 
mTORC2-mediated pAKTS473 activation. Furthermore activation of these BCR-signals with immobilised 
anti-IgM beads strongly protects CLL cells from apoptosis as indicated by a decrease in cleaved 
caspase-3 and PARP compared to the control, but was reversed upon treatment with PF-04691502 
(Supplementary Figure 4A).  
 
PF-04691502 inhibits CXCL12 induced signaling and subsequent migration 
In vivo, CXCL12 signaling enables CLL cells to enter and become retained within protective lymph node 
microenvironments.12 Therefore, disruption of CXCL12/CXCR4 signaling provides an attractive 
therapeutic target.12 Here, CLL cells treated with CXCL12 (200ng/ml) for 10 minutes showed increased 
pAKTS473, pS6KT389 and pS6S235/236 which was reversed following treatment with PF-04691502 (Figure 
5A). In contrast, pERKT202/Y204 was not affected by PF-04691502 pre-treatment, potentially due to 
downstream signalling from Syk/Ras being unaffected by PF-04691502. Next, we determined the 
effect of PF-04691502 on CLL motility in an in vitro transwell migration assay. Treatment of CLL cells 
with PF-04691502 showed no significant effect on basal CLL motility, however CXCL12-induced CLL 
motility was significantly abrogated following pre-treatment with PF-04691502 for only 30 minutes 
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(p=0.02 and p=0.025 at 1.25 and 2.5µM, respectively) (Figure 5B) and was not dependent on reduced 
expression of CXCR4 (Supplementary Figure 4B). These data indicate that PF-04691502 inhibits CXCL12 
signalling and subsequent migration, which has potential importance for CLL cells accessing the 
protective lymph node microenvironment in vivo. 
 
PF-04691502 has efficacy in murine Eµ-TCL1 CLL cells ex vivo 
Next, we examined whether PF-04691502 displayed activity against murine Eµ-TCL1 tumor cells, 
isolated and cultured ex-vivo. Eµ-TCL1 tumor cells were isolated from the spleens of tumor-bearing 
mice and then treated with anti-IgM or CXCL12 in the presence or absence of PF-04691502 and the 
effects on downstream signaling investigated by immunoblotting. PF-04691502 substantially blocked 
signaling induced by both stimuli, reducing pAKTT308, pAKTS473, pS6KT389 and pS6S235/236 to below 
background levels, with lesser effects on pERKT202/Y204 at 2.5-25nM PF-04691502 (Figure 6A and 6B). 
These effects translated into an ability of PF-04691502 to efficiently kill Eµ-TCL1 tumor cells (n=8 
different tumors) (Figure 6C) and inhibit migration towards CXCL12 (Figure 6D). These data 
recapitulated those seen with primary human CLL cells above.  
 
In vivo efficacy of PF-04691502 
Finally, we explored the activity of PF-04691502 in vivo. Cohorts of mice were inoculated with Eµ-TCL1 
tumor cells and when tumor was visible in the blood (approximately 21 days), mice were randomised 
to receive 5 or 10mg/kg/day PF-04691502 or vehicle control by oral gavage and the leukemic burden 
in the blood was monitored over the following 14 days (Figure 7A). After receiving the drug a small 
but significant lymphocytosis was observed which persisted for approximately 4-7 days. Subsequently, 
PF-04691502 elicited a marked reduction in leukemic burden compared to the vehicle control 
(p=0.0001), indicating a profound anti-tumor effect. Both drug doses demonstrated the same efficacy, 
indicating that the minimum effective dose was achieved. Fourteen days post treatment vehicle-
recipient animals exhibited a terminal disease and were sacrificed alongside mice receiving 
10mg/kg/day PF-04691502 and the effects of the drug on multiple tissues including the spleen, lymph 
nodes and bone marrow (Figure 7B-D) determined. Mice receiving 5 mg/kg/day were maintained on 
drug for survival experiments. Visual assessment and weighing of the spleen illustrated the ability of 
the drug to prevent tumor expansion at this site (Figure 7B and 7C); which was confirmed by 
enumerating the number of tumor cells (Figure 7D). In fact, no increase in splenic mass was observed 
compared to normal healthy C57BL/6 mice, whereas vehicle-treated mice exhibited a 4-8 fold increase 
in splenic mass, alongside a tumor cell count an order of magnitude higher than PF-04691502 treated 
mice. Next, we examined the macroscopic appearance of the spleen using Hematoxylin and eosin 
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(H&E) staining (Supplementary Figure 5A). These images indicate that the Eμ-TCL1 leukemias destroy 
the typical splenic architecture, whereas this was largely prevented by PF-04691502 treatment. In 
addition to the spleen, we also observed similar effects of the drug reducing tumor expansion in the 
lymph nodes and bone-marrow (Figure 7D). Cumulatively, these effects significantly enhanced survival 
in 5 mg/kg/day-recipient animals (p=<0.0001) (Supplementary Figure 5B). Furthermore, mice showed 
a small but significant reduction in normal B-cell number but no significant reduction in normal T-cell 
number (data not shown). These data indicate that PF-04691502 has substantial efficacy in vivo, 
warranting further investigation of dual PI3K/mTOR inhibitors for the treatment of CLL. 
 
DISCUSSION 
Treatment of CLL patients with ibrutinib and idelalisib have produced impressive clinical responses, 
however the agents are not curative and only suppress the disease. Therefore, identifying an agent 
that can purge CLL cells from the protective lymph node and bone marrow niches in combination with 
substantive tumor toxicity may prove essential for an eventual cure.  Our results showed that PF-
04691502 inhibited BCR and CXCL12 induced signaling, resulting in caspase-dependent apoptosis of 
CLL cells in vitro at nanomolar concentrations, whilst treatment of normal B and T cells resulted in 
little to no death. Caspase-dependency was confirmed with the pan-caspase inhibitor ZVAD.fmk and 
was preceded by the pro-apoptotic conformational change in Bax. Bax activation correlated with the 
induction of the BH3-only Bcl-2 family members Noxa and Puma suggesting activation of the intrinsic 
apoptotic pathway.  However, since 17p del cases displayed equivalent sensitivity to PF-04691502 as 
wildtype samples, the pathway leading to Noxa and Puma induction after PF-04691502 treatment may 
be TP53-independent. The mechanism behind the Noxa and Puma induction is currently unknown and 
is the subject of our ongoing studies. PF-04691502 induced apoptosis independently of known 
prognostic markers, which is consistent with findings with idelalisib in CLL.19 However, an intriguing 
finding was the enhanced apoptotic potency of PF-04691502 in comparison to idelalisib.19,42 This 
increased cytotoxicity against CLL cells by PF-04691502 may be due to inhibition of more than one 
PI3K isoform or more likely due to the co-inhibition of PI3K and mTORC1/2. Evidence in mantle cell 
lymphoma to support this has shown constitutive PI3Kα signaling limits the efficacy of PI3Kδ selective 
inhibitors.43 Functional redundancy between PI3K isoforms in the survival of neutrophils has 
previously been shown,15 therefore it may be theorized that in CLL cells other PI3K isoforms may 
compensate for the selective inhibition of PI3Kδ with idelalisib, resulting in lower levels of cytotoxicity 
with this drug. However the γ/δ inhibitor IPI-145 did not increase CLL cell apoptosis more than 
idelalisib in vitro.44 In contrast, the dual PI3Kα/γ inhibitor PIK90 and the pan-PI3K inhibitor NVP-
BKM120 (Buparlisib) induce substantially more CLL cell apoptosis,23,45 than single isoform inhibitors.19 
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The potential caveat to inhibition of more than a single PI3K isoform is the possibility of greater toxicity 
to normal tissues. However, a number of pan-PI3K inhibitors and dual PI3K/mTOR inhibitors are 
currently progressing through clinical trials for various malignancies with promising results.46 
Interestingly, long-term PI3Kα inhibition was not detrimental to mice and in fact protected against a 
reduction in insulin sensitivity, glucose tolerance and fat accumulation.47 During our study we 
combined inhibitors that targeted specific isoforms of PI3K and mTOR; replicating our findings with 
PF-04691502. Although combining the PI3Kα/β/δ/γ inhibitors or idelalisib with the mTOR inhibitor 
everolimus induced substantial apoptosis, PF-04691502 alone still induced significantly more. This 
may be because everolimus inhibits predominately mTORC1, whilst PF-04691502 inhibits both 
mTORC1 and mTORC2, which is essential to inhibit the positive feedback and subsequent 
phosphorylation of AKTS473.  However, these data suggest that an mTORC1 inhibitor, and maybe more 
importantly a dual mTORC1/2 inhibitor, in combination with idelalisib may be more therapeutically 
beneficial in the treatment of CLL than PI3K inhibition alone.  
 
Ligation of the BCR occurs primarily in the protective lymph node microenvironment48 and is thought 
to be crucial for survival of the malignant clone.40 Furthermore, CXCL12 induces migration of the CLL 
cells from the periphery into the lymph node promoting their retention within protective 
microenvironments.12 CXCL12/CXCR4 signaling has previously been shown to inhibit spontaneous cell 
death and chemotherapy-induced apoptosis.49  Therefore, our finding that PF-04691502 could 
overcome pro-survival anti-IgM induced signaling and substantially inhibit CXCL12 signaling and 
subsequent CLL migration is of clear importance. This is also in agreement with what has been 
described for idelalisib.20 These results indicate that PF-04691502 may have similar clinical 
characteristics to other kinase inhibitors, where the inhibition of BTK, PI3Kδ or SYK results in reduced 
interaction of CLL cells with its protective microenvironments, re-distribution of the tumor cells from 
tissues to the blood and some cellular toxicity.19,50 This resulted in clinical activity whereby patients 
undergo rapid lymph node shrinkage and lymphocytosis within weeks of treatment initiation.7,11,20 Due 
to the relatively low toxicity of these agents alone on CLL cells, combining them with Bcl-2 antagonists 
(ABT-199) has been proposed. However, given the trend for greater Mcl-1 expression in CLL patient 
lymph nodes,51 which is regulated by microenvironmental factors through PI3K, PI3K inhibition may 
have greater efficacy. This raises the question as to whether targets downstream of PI3K, such as AKT, 
are equally tractable. However, current data suggest not, as CLL cells treated with AKT inhibitors 
(MK2206 and AZD5363) required concentrations in excess of 10µM to elicit relatively small amounts 
of apoptosis and clinical trials have stopped recruiting (NCT01369849).  
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Tumor cell redistribution was also evident in the Eµ-TCL1 model with a transient lymphocytosis seen 
in the blood concomitant with reduced tumor load in the secondary lymphoid organs and bone 
marrow upon PF-04691502 treatment. Such lymphocytosis is likely a consequence of reduced 
chemokine receptor expression or signal inhibition. Interestingly, although PF-04691502 treatment 
prevented accumulation of tumor in the spleen and caused protection of the global splenic 
architecture, tumor was still evident, even in the presence of PF-04691502. Therefore, these tumor 
deposits likely reflect treatment-resistant reservoirs, which require additional interventions with 
other treatment modalities. This is the basis for our on-going studies. 
 
The results from this study show that simultaneous inhibition of all four class 1 PI3K isoforms in 
combination with the inhibition of mTOR kills CLL cells more potently than selective PI3Kδ inhibition 
alone. The data generated with systems mimicking ongoing BCR stimulation and stromal support 
indicates its ability to overcome protective microenvironment signalling in vivo. These results are 
supported by in vivo experimentation using the Eµ-TCL1 mouse model that further indicates that PF-
04691502 may prove therapeutically useful for the treatment of CLL. Further studies are now required 
to investigate its key modes of action and explore its utility in combination with other treatment 
modalities. 
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FIGURE LEGENDS 
Figure 1. Inhibition of mTOR augments AKT signaling in CLL which can be overcome by a dual 
PI3K/mTOR inhibitor. (A) CLL cells were pre-treated with Everolimus (1 µM) or PF-04691502 (1 µM) 
for 2.5 hours prior to treatment with soluble anti-IgM (IgM) for 15 minutes. Immunoblotting was 
performed for phosphorylated AKT (pAKTS473), S6 kinase (pS6KT389) and S6 (pS6 ribsosomal 
subunitS235/236). Bcl-2 was used as a loading control. Graphs (B-E) represent the fold change in pAKTS473, 
pS6KT389, pS6S235/236 and AKTT308 compared to the untreated basal control following the various 
treatments described above (n=7, 6, 7 and 5 respectively). * represents p<0.05. Error bars represent 
SEM. 
 
Figure 2. PF-04691502 reduces cell viability of CLL cells independently of prognostic markers. (A) CLL 
samples (n=25) and normal B (CD19+) and T cells (CD3+) (n=5) were treated in the presence or absence 
of PF-04691502 (0.0049-40µM) for 24 hours. Cell viability was calculated using AnnexinV/PI assays 
and measured by flow cytometry. For comparison a proportion of the same CLL samples were treated 
with idelalisib (0.0049-40µM) (n=12). (B) CLL samples (n=6) were treated with PF-04691502 (0.0025-
2.5µM) for 24-72h in a small cohort of 6 patients (3 low IC50 and 3 high IC50 at 24h). (C-E) Correlation 
of the response to PF-04691502 with prognostic markers IGHV (n=21), ZAP70 (n=23) and CD38 (n=23).  
Error bars represent SEM. 
 
Figure 3. PF-04691502 induces the intrinsic apoptosis pathway following PI3K/mTOR pathway 
inhibition. Immunoblotting was utilised to show (A) Expression of the Bcl-2 family of pro-apoptotic 
proteins namely Noxa and Puma in resting non-activated cells. pAKTS473 and pS6KT389 were used to 
confirm PF-04691502 treatment (18h) had inhibited the PI3K/mTOR pathway. HSC70 was the loading 
control. The figure is representative of 9 independent experiments. (B) BAX conformational change 
was investigated in the presence or absence of PF-04691502, immunoprecipitation with the BAX 6A7 
was performed as described (Supplementary methods). IgH and IgL were included to confirm identical 
quantities of antibody were used for the immunoprecipitation. Blot is representative of 4 independent 
experiments.  (C) Cleavage of caspase-3 and its substrate PARP (marker of apoptosis), representative 
blot of 10 independent experiments. (D) CLL samples (n=7) were treated with PF-04691502 as above 
but with or without the pan-caspase inhibitor ZVAD.fmk and analysed by flow cytometry for Annexin 
V/PI negativity. (E) Stromal fibroblasts (HFFF2) were co-cultured with CLL cells and the whole well 
treated in the presence or absence of continuous PF-04691502 (2.5µM) for 24h. CLL cells were 
removed by pipetting (Supplementary Figure 3D) or scraping (Figure 3E) and cell viability analysed 
using Annexin V/PI analysis by flow cytometry (n=7). (F) The assay was performed as (E) except that 
the CLL cells were pre-treated for 1 hours with PF-04691502 prior to drug washed out and the treated 
CLL cells were plated into wells containing stromal fibroblasts (n=7).  Error bars represent SEM. 
(Method in supplementary data). No difference was observed between scraping all cells or washing 
off only the CLL cells (compare Figure 3E and Supplementary Figure 3D).  
 
Figure 4. PF-04691502 inhibits anti-IgM induced signaling 
CLL cells were treated with (A) soluble anti-IgM (n=9) and (B) immobilised anti-IgM beads (n=5) prior 
to evaluation of downstream signalling in the presence and absence of PF-04691502 (0.0025-2.5µM) 
by immunoblot analysis. Representative cases are shown. CLL cells were treated for an hour with PF-
04691502 prior to soluble/immobilised anti-IgM addition. pAKTT308 and pS6KT389 were used as markers 
of PI3K signalling,  pAKTS473 and pS6S235/236 were used as markers of mTOR signalling and pERKT202/Y204 
was used as a marker of MAPK signalling.  
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Figure 5. PF-04691502 inhibits CXCL12 signalling and subsequent migration 
(A) CLL cells were treated with 200ng/ml CXCL12 for the times indicated in the presence or absence 
of PF-04691502 (0.25-2.5µM). PF-04691502 was added 30 minutes prior to the addition of CXCL12. 
Immunoblotting was performed pAKTS473, pS6KT389, pS6S235/236, pERKT202/Y204, total proteins and the 
loading control Bcl-2 were investigated, immunoblot representative of 6 independent experiments. 
(B) Using a transwell migration assay we evaluated the migration of CLL cells towards 200ng/ml 
CXCL12 in the presence or absence of PF-04691502 (1.25-2.5µM). Flow cytometry was used to count 
the number of cells which had passed through the transwell filter (n=5). Error bars represent SEM. 
(Method in supplementary data). 
 
Figure 6. PF-04691502 inhibits anti-IgM and CXCL12 induced signalling in Eµ-TCL-1 murine cells. 
Eµ-TCL-1 cells were removed from mice and grown in vitro. Eµ-TCL-1 cells were treated with (A) anti-
IgM (5-15mins) or (B) 200ng/ml CXCL12 in the presence or absence of PF-04691502 (0.0025-2.5µM) 
and the effects on downstream signalling (pAKTT308, pAKTS473, pS6KT389, pS6S235/236 and pERKT202/Y204) 
investigated by immunoblotting. HSC70 was used as a loading control. (C) Viability of Eµ-TCL-1 cells by 
PF-04691502 was evaluated by AnnexinV/PI assays and represented as percentage viable cells. (D) 
Migration was performed as previously described in Figure 5B. Error bars represent SEM. 
 
Figure 7. The effect of PF-04691502 in the Eµ-TCL-1 mouse model 
Mice inoculated with Eµ-TCL-1 tumor cells were treated by oral gavage with 5 or 10mg/kg/d 
PF-04691502 or placebo control over 14 days of continual treatment once the emergence of a 
leukemic phase occurred at day 21 (depicted by the arrow). (A) Peripheral leukemic (CD5+CD220+) cell 
number was evaluated by flow cytometry in the presence of PF-04691502 or the vehicle control. (B) 
Illustration of the spleen sizes from mice treated with 10mg/kg/day PF-04691502 or vehicle control 
compared to the WT mouse C57BL/6. (C) Represents the spleen weights from (B). (D) Leukemic cell 
number was also investigated in various organs including spleens (SPL), lymph nodes (LN) and bone 
marrow (BM) following treatment with PF-04691502 or the vehicle control. Error bars represent SEM. 
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